<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.1.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center;"><font style="font-weight: bold; color: rgb(0, 0, 0);">As filed with the Securities and Exchange Commission on March 7, 2022<br>
      </font><br>
    </div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-______</div>
    <div style="padding-top: 1pt;">
      <div>
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">UNDER</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">ADMA BIOLOGICS, INC.</div>
    <div style="text-align: center; color: rgb(0, 0, 0);">(Exact name of registrant as specified in its charter)</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3ccacd945df942cd9bf66b79c5346369">

        <tr>
          <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">56-2590442</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(State or other jurisdiction of</div>
            <div style="text-align: center; color: rgb(0, 0, 0);"> incorporation or organization)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(I.R.S. Employer Identification No.)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">465 State Route 17</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Ramsey, New Jersey</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">07446</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Address of Principal Executive Offices)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">AMENDED AND RESTATED ADMA BIOLOGICS, INC. 2014 OMNIBUS INCENTIVE COMPENSATION PLAN</div>
    <div style="text-align: center; color: rgb(0, 0, 0);">(Full title of the plan)</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zefd8217aa58f45da9fa593609708b541">

        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Adam S. Grossman&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><br>
            </div>
          </td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">President and Chief Executive Officer</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">David C. Schwartz, Esq.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ADMA Biologics, Inc.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Morgan, Lewis &amp; Bockius LLP</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">465 State Route 17</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">502 Carnegie Center</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Ramsey, New Jersey 07446</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Princeton, New Jersey 08540</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(201) 478-5552</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">&#160;(609) 919 6600</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Name, address, telephone number,</div>
            <div style="text-align: center; color: rgb(0, 0, 0);"> including area code, of agent for service)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(With copies to)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; color: rgb(0, 0, 0);">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
      company.&#160; See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z144d6d8b2e7e4cffac4c50ac56fd9e5b">

        <tr>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Large accelerated filer &#9744;</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Accelerated filer &#9744;</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Non-accelerated filer &#9746;</div>
            <div style="text-align: center; color: rgb(0, 0, 0);">&#160;(Do not check if a smaller reporting company)</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Smaller reporting company &#9746;</div>
          </td>
          <td style="width: 20.01%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Emerging growth company &#9744;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; color: rgb(0, 0, 0);">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial
      accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160; &#9744;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0);"> <br>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0);">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">EXPLANATORY NOTE</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Registration Statement on Form S-8 (this &#8220;Registration Statement&#8221;) is being filed for the purpose of registering an additional 7,832,552 shares of common stock, <font style="color: rgb(0, 0, 0);">$0.0001</font>
      par value per share (the &#8220;<font style="color: rgb(0, 0, 0);">Common Stock</font>&#8221;), of <font style="color: rgb(0, 0, 0);">ADMA Biologics, Inc</font>. (the &#8220;<font style="color: rgb(0, 0, 0);">Registrant</font>&#8221;) that were added to the shares
      authorized for issuance under the <font style="color: rgb(0, 0, 0);">Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan</font> (the &#8220;2014 <font style="color: rgb(0, 0, 0);">Plan</font>&#8221;) pursuant to an &#8220;evergreen&#8221;
      provision contained in the 2014 Plan, for which Registration Statements on Form S-8 relating to the same employee benefit plan are effective. Pursuant to the evergreen provision, on January 1 of each year through 2022, the number of shares authorized
      for issuance under the 2014 Plan is automatically increased by a number equal to 4% of the outstanding shares of Common Stock as of the end of Registrant&#8217;s immediately preceding fiscal year, or any lesser number of shares of Common Stock determined
      by the board of directors of the Registrant.</div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify;">The Registrant previously filed the Registration Statements on Form S-8 (File Nos. 333-254770, 333-237658, 333-229921, 333-224492, 333-220058 and 333-204590) on March 26, 2021, April 13, 2020, February 27, 2019, April
      27, 2018, August 18, 2017 and May 29, 2015, respectively, with the Securities and Exchange Commission (the &#8220;Commission&#8221;) to register an aggregate of 13,130,656 shares of Common Stock that were authorized for issuance under the 2014 Plan
      (collectively, the &#8220;Prior Registration Statements&#8221;). Upon the effectiveness of this Registration Statement, an aggregate of 20,963,208<font style="color: rgb(0, 0, 0);">&#160;</font>shares of Common Stock will be registered for issuance from time to time
      under the 2014 Plan. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein.
      Only those items of Form S-8 containing new information not contained in the Prior Registration Statements are presented herein.</div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">INCORPORATION BY REFERENCE</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements, with respect to securities offered pursuant to the <font style="color: rgb(0, 0, 0);">2014
        Plan,</font> are hereby incorporated by reference.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The following documents previously filed by the <font style="color: rgb(0, 0, 0);">Registrant</font> with the Commission are incorporated herein by reference and shall be deemed to be a part hereof:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; The <font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">Registrant&#8217;s</font> Annual Report on Form 10-K for the year ended <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000411/adma_10k.htm">December 31, 2020</a>, filed with the Commission on March 25, 2021;</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">(2)&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; The Registrant&#8217;s Quarterly Reports on Form 10-Q for the quarters ended <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000657/adma_10q.htm">March 31, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121027950/brhc10027771_10q.htm">June 30, 2021</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121037463/brhc10030513_10q.htm">September 30,
        2021</a>, filed with the Commission on May 12, 2021, August 11, 2021 and November 10, 2021, respectively.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The <font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">Registrant&#8217;s Current Reports on Form 8-K filed with the Commission on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000004/e620188_8k-adma.htm">January 4, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000065/e620220_8k-adma.htm">January 26, 2021</a>,
        <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000106/e620239_8k-adma.htm">February 1, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000126/e620246_8k-adma.htm">February 3,
          2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000299/e620325_8k-adma.htm">March 2, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000549/e620523_8k-adma.htm">April
          28, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000749/e620651_8k-adma.htm">May 28, 2021 (first filing), </a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000751/e620652_8k-adma.htm">May 28, 2021 (second filing)</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000119380521000863/e620714_8k-adma.htm">June
          14, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121024961/brhc10027069_8k.htm">July 20, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121025680/brhc10027259_8k.htm">July




          27, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121027961/brhc10027960_8k.htm">August 12, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121028496/brhc10028121_8k.htm">August




          16, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121028679/brhc10028148_8k.htm">August 17, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121030391/ny20000594x2_8k.htm">September




          3, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121033302/brhc10029407_8k.htm">October 1, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121034761/brhc10029850_8k.htm">October




          18, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121034997/brhc10029951_8k.htm">October 20, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121035103/brhc10029970_8k.htm">October 21, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121035296/brhc10030026_8k.htm">October 25, 2021</a>,
        <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121038017/brhc10030868_8k.htm">November 16, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121040956/brhc10031690_8k.htm">December 9,
          2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036121042611/brhc10032042_8k.htm">December 21, 2021</a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122001782/brhc10032849_8k.htm">January 18, 2022</a> (provided that any portions of such report that are deemed furnished and</font> not filed pursuant to instructions to Form
      8-K shall not be incorporated by reference into this Registration Statement); and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The description of Common Stock set forth in Exhibit 4.11 to the <font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">Registrant&#8217;s</font> Annual Report on Form
      10-K filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380521000411/adma_ex411.htm">March 25, 2021</a> pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;),
      including any amendment or report filed for the purpose of updating such description.</div>
    <div> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In addition, all documents that the <font style="color: rgb(0, 0, 0);">Registrant</font> files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of
      this Registration Statement (except for any portions of the <font style="color: rgb(0, 0, 0);">Registrant&#8217;s</font> Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with
      the Commission), but prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be
      incorporated by reference in this Registration Statement and to be a part hereof from the date of filing such documents.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">For purposes of this Registration Statement, any document or statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
      superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document or statement in such document. Any such
      statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBITS</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zca005735bc794b7cb64551b2e3cc3f1b">

        <tr>
          <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">EXHIBIT</div>
              <div>NUMBER</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">DESCRIPTION</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036121042611/brhc10032042_ex4-1.htm">4.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Rights Agreement, dated as of December 20, 2021, by and between ADMA Biologics, Inc. and Continental Stock Transfer and Trust Company, as rights agent (incorporated by reference to Exhibit
              4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 21, 2021).</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="brhc10034675_ex5-1.htm">5.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Opinion of Morgan, Lewis and Bockius LLP, counsel for the Registrant, regarding the legal validity of the shares of Common Stock being registered on this Registration Statement (filed
              herewith).</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380517001506/e616485_ex10-1.htm">10.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-8
              filed on August 18, 2017).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="brhc10034675_ex5-1.htm">23.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Consent of Morgan, Lewis and Bockius LLP (contained in Exhibit 5.1).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="brhc10034675_ex23-2.htm">23.2</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Consent of CohnReznick LLP, the Registrant&#8217;s Independent Registered Public Accounting Firm <font style="color: rgb(0, 0, 0);">(filed herewith).</font></div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="#poa">24.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Power of Attorney (included on signature page).</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="brhc10034675_ex107.htm">107</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Filing Fee Exhibit</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
      and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ramsey, State of New Jersey, on this 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day of March, 2022.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf6c3b9031ce547d88629b3fce9484775">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ADMA Biologics, Inc.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">(Registrant)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Brian Lenz</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Name: Brian Lenz</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Title: Executive Vice President and Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><a name="poa"><!--Anchor--></a>KNOW BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Adam S. Grossman and Brian Lenz, and each of them, the
      undersigned&#8217;s true and lawful attorneys-in-fact and agents, with full power of substitution and revocation, for and in the undersigned&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
      amendments) to this Registration Statement on Form S-8 (this &#8220;Registration Statement&#8221;) and any registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and to file the same, with all
      exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to
      be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratify and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitutes, may lawfully do or cause to be done by
      virtue thereof.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on the date
      listed below.</div>
    <div style="text-align: justify;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z26ee838ed42a4d749018d9bbbefead86">

        <tr>
          <td style="width: 41.39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-weight: bold;">Signature</div>
          </td>
          <td style="width: 1.86%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 30.38%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Capacity</div>
          </td>
          <td style="width: 2.76%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 23.6%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div style="text-align: justify; margin-right: 54.2pt;">&#160;</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Adam S. Grossman</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div>President and Chief Executive Officer, Director</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">
            <div style="text-align: justify;">March 7, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Adam S. Grossman</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div>(Principal Executive Officer)</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Brian Lenz</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div>Executive Vice President and Chief Financial Officer</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">
            <div style="text-align: justify;">
              <div>
                <div>March 7, 2022</div>
              </div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Brian Lenz</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div>(Principal Financial Officer and Principal Accounting Officer)</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Steven A. Elms</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div>Chairman of the Board of Directors&#160;</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">
            <div style="text-align: justify;">
              <div>
                <div>March 7, 2022</div>
              </div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Steven A. Elms</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Dr. Jerrold B. Grossman</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div>Vice Chairman of the Board of Directors</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">
            <div style="text-align: justify;">
              <div>
                <div>March 7, 2022</div>
              </div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Dr. Jerrold B. Grossman</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Martha J. Demski</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div style="text-align: justify;">Director</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">
            <div style="text-align: justify;">
              <div>
                <div>March 7, 2022</div>
              </div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Martha J. Demski</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Bryant E. Fong</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div style="text-align: justify;">Director</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">
            <div style="text-align: justify;">
              <div>
                <div>March 7, 2022</div>
              </div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Bryant E. Fong</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div style="text-align: justify;">&#160;</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Lawrence P. Guiheen</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div style="text-align: justify;">Director</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">
            <div style="text-align: justify;">
              <div>
                <div>March 7, 2022</div>
              </div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Lawrence P. Guiheen</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">&#160;</td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Young T. Kwon</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">
            <div style="text-align: justify;">Director</div>
          </td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">
            <div style="text-align: justify;">
              <div>
                <div>March 7, 2022</div>
              </div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.39%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Young T. Kwon</div>
          </td>
          <td style="width: 1.86%; vertical-align: top;">&#160;</td>
          <td style="width: 30.38%; vertical-align: top;">&#160;</td>
          <td style="width: 2.76%; vertical-align: top;">&#160;</td>
          <td style="width: 23.6%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div> <br>
    </div>
    <br>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "brhc10034675_s8.htm", "description": "S-8", "secsgml_size_bytes": 50309}]
{"company-data": {"conformed-name": "ADMA BIOLOGICS, INC.", "cik": "0001368514", "assigned-sic": "2836", "irs-number": "562590442", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-263345", "film-number": "22718684"}, "business-address": {"street1": "C/O ADMA BIOLOGICS, INC.", "street2": "465 STATE ROUTE 17", "city": "RAMSEY", "state": "NJ", "zip": "07446", "phone": "(201) 478-5552"}, "mail-address": {"street1": "C/O ADMA BIOLOGICS, INC.", "street2": "465 STATE ROUTE 17", "city": "RAMSEY", "state": "NJ", "zip": "07446"}, "former-company": {"former-conformed-name": "R&R ACQUISITION VI, INC", "date-changed": "20060707"}}
As filed with the Securities and Exchange Commission on March 7, 2022
Registration No. 333-______
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
56-2590442
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification No.)
465 State Route 17
Ramsey, New Jersey
07446
(Address of Principal Executive Offices)
(Zip Code)
AMENDED AND RESTATED ADMA BIOLOGICS, INC. 2014 OMNIBUS INCENTIVE COMPENSATION PLAN
(Full title of the plan)
Adam S. Grossman
President and Chief Executive Officer
David C. Schwartz, Esq.
ADMA Biologics, Inc.
Morgan, Lewis & Bockius LLP
465 State Route 17
502 Carnegie Center
Ramsey, New Jersey 07446
Princeton, New Jersey 08540
(201) 478-5552
(609) 919 6600
(Name, address, telephone number,
including area code, of agent for service)
(With copies to)
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
      company.  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
(Do not check if a smaller reporting company)
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial
      accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 (this "Registration Statement") is being filed for the purpose of registering an additional 7,832,552 shares of common stock,
$0.0001
par value per share (the "
Common Stock
"), of
ADMA Biologics, Inc
. (the "
Registrant
") that were added to the shares
      authorized for issuance under the
Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan
(the "2014
Plan
") pursuant to an "evergreen"
      provision contained in the 2014 Plan, for which Registration Statements on Form S-8 relating to the same employee benefit plan are effective. Pursuant to the evergreen provision, on January 1 of each year through 2022, the number of shares authorized
      for issuance under the 2014 Plan is automatically increased by a number equal to 4% of the outstanding shares of Common Stock as of the end of Registrant's immediately preceding fiscal year, or any lesser number of shares of Common Stock determined
      by the board of directors of the Registrant.
The Registrant previously filed the Registration Statements on Form S-8 (File Nos. 333-254770, 333-237658, 333-229921, 333-224492, 333-220058 and 333-204590) on March 26, 2021, April 13, 2020, February 27, 2019, April
      27, 2018, August 18, 2017 and May 29, 2015, respectively, with the Securities and Exchange Commission (the "Commission") to register an aggregate of 13,130,656 shares of Common Stock that were authorized for issuance under the 2014 Plan
      (collectively, the "Prior Registration Statements"). Upon the effectiveness of this Registration Statement, an aggregate of 20,963,208
shares of Common Stock will be registered for issuance from time to time
      under the 2014 Plan. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein.
      Only those items of Form S-8 containing new information not contained in the Prior Registration Statements are presented herein.
INCORPORATION BY REFERENCE
In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements, with respect to securities offered pursuant to the
2014
        Plan,
are hereby incorporated by reference.
The following documents previously filed by the
Registrant
with the Commission are incorporated herein by reference and shall be deemed to be a part hereof:
(1)           The
Registrant's
Annual Report on Form 10-K for the year ended
December 31, 2020
, filed with the Commission on March 25, 2021;
(2)           The Registrant's Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2021
,
June 30, 2021
and
September 30,
        2021
, filed with the Commission on May 12, 2021, August 11, 2021 and November 10, 2021, respectively.
(3)          The
Registrant's Current Reports on Form 8-K filed with the Commission on
January 4, 2021
,
January 26, 2021
,
February 1, 2021
,
February 3,
          2021
,
March 2, 2021
,
April
          28, 2021
,
May 28, 2021 (first filing),
May 28, 2021 (second filing)
,
June
          14, 2021
,
July 20, 2021
,
July

          27, 2021
,
August 12, 2021
,
August

          16, 2021
,
August 17, 2021
,
September

          3, 2021
,
October 1, 2021
,
October

          18, 2021
,
October 20, 2021
,
October 21, 2021
,
October 25, 2021
,
November 16, 2021
,
December 9,
          2021
,
December 21, 2021
, and
January 18, 2022
(provided that any portions of such report that are deemed furnished and
not filed pursuant to instructions to Form
      8-K shall not be incorporated by reference into this Registration Statement); and
(4)          The description of Common Stock set forth in Exhibit 4.11 to the
Registrant's
Annual Report on Form
      10-K filed with the Commission on
March 25, 2021
pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
      including any amendment or report filed for the purpose of updating such description.
In addition, all documents that the
Registrant
files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of
      this Registration Statement (except for any portions of the
Registrant's
Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with
      the Commission), but prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be
      incorporated by reference in this Registration Statement and to be a part hereof from the date of filing such documents.
For purposes of this Registration Statement, any document or statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
      superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document or statement in such document. Any such
      statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
EXHIBITS
EXHIBIT
NUMBER
DESCRIPTION
4.1
Rights Agreement, dated as of December 20, 2021, by and between ADMA Biologics, Inc. and Continental Stock Transfer and Trust Company, as rights agent (incorporated by reference to Exhibit
              4.1 to the Company's Current Report on Form 8-K filed with the SEC on December 21, 2021).
5.1
Opinion of Morgan, Lewis and Bockius LLP, counsel for the Registrant, regarding the legal validity of the shares of Common Stock being registered on this Registration Statement (filed
              herewith).
10.1
Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant's Registration Statement on Form S-8
              filed on August 18, 2017).
23.1
Consent of Morgan, Lewis and Bockius LLP (contained in Exhibit 5.1).
23.2
Consent of CohnReznick LLP, the Registrant's Independent Registered Public Accounting Firm
(filed herewith).
24.1
Power of Attorney (included on signature page).
107
Filing Fee Exhibit
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
      and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ramsey, State of New Jersey, on this 7
th
day of March, 2022.
ADMA Biologics, Inc.
(Registrant)
By:
/s/ Brian Lenz
Name: Brian Lenz
Title: Executive Vice President and Chief Financial Officer
KNOW BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Adam S. Grossman and Brian Lenz, and each of them, the
      undersigned's true and lawful attorneys-in-fact and agents, with full power of substitution and revocation, for and in the undersigned's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
      amendments) to this Registration Statement on Form S-8 (this "Registration Statement") and any registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"), and to file the same, with all
      exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to
      be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratify and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitutes, may lawfully do or cause to be done by
      virtue thereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on the date
      listed below.
Signature
Capacity
Date
/s/ Adam S. Grossman
President and Chief Executive Officer, Director
March 7, 2022
Adam S. Grossman
(Principal Executive Officer)
/s/ Brian Lenz
Executive Vice President and Chief Financial Officer
March 7, 2022
Brian Lenz
(Principal Financial Officer and Principal Accounting Officer)
/s/ Steven A. Elms
Chairman of the Board of Directors
March 7, 2022
Steven A. Elms
/s/ Dr. Jerrold B. Grossman
Vice Chairman of the Board of Directors
March 7, 2022
Dr. Jerrold B. Grossman
/s/ Martha J. Demski
Director
March 7, 2022
Martha J. Demski
/s/ Bryant E. Fong
Director
March 7, 2022
Bryant E. Fong
/s/ Lawrence P. Guiheen
Director
March 7, 2022
Lawrence P. Guiheen
/s/ Young T. Kwon
Director
March 7, 2022
Young T. Kwon